Flecainide, a therapeutic option in a patient with long QT syndrome type 3 caused by the heterozygous V411M mutation in the SCN5A gene

Rev Esp Cardiol (Engl Ed). 2012 Nov;65(11):1058-9. doi: 10.1016/j.recesp.2012.03.014. Epub 2012 Jun 19.

[Article in English, Spanish]

Authors

José Ignacio Carrasco, Isabel Izquierdo, Pilar Medina, Miguel Ángel Arnau, Antonio Salvador, Esther Zorio

PMID: 22721569
DOI: 10.1016/j.recesp.2012.03.014

No abstract available

Publication types

Case Reports
Letter
Research Support, Non-U.S. Gov't

MeSH terms

Anti-Arrhythmia Agents / therapeutic use*
Cardiac Conduction System Disease
Electrocardiography
Female
Flecainide / therapeutic use*
Heterozygote
Humans
Infant
Long QT Syndrome / drug therapy*
Long QT Syndrome / genetics*
Mutation / physiology
NAV1.5 Voltage-Gated Sodium Channel / genetics*

Substances

Anti-Arrhythmia Agents
NAV1.5 Voltage-Gated Sodium Channel
SCN5A protein, human
Flecainide

Supplementary concepts

Long QT syndrome type 3